Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT
2025-522404-24-01Phase 3Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluorine f 18 ara-g in bronchial carcinoma, sponsored by Amsterdam University Medical Center. Primary endpoints: Absolute difference in SUV uptake between both [18F]F-AraG PET scanning timepoints, Relative difference in SUV uptake between both [18F]F-AraG PET scanning timepoints and 2 more. Planned start Jan 2026; status: authorised.
02
Drugs
fluorine f 18 ara-g
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on 2025-522404-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522404-24-01.